RIGL Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Growing Multi-product Commercial BusinessGrowth across the commercial portfolio indicates expanding demand beyond a single therapy and supports a more diversified revenue base. TAVALISSE’s record quarter and REZLIDHIA’s strong growth can improve operating leverage and provide a foundation for continued investment in new products.
Strong Profitability And Free Cash FlowPositive operating and free cash flow, combined with very high gross margins and positive operating profitability, marks a substantial improvement from earlier loss-making periods. This internally generated liquidity can fund development and commercialization while reducing reliance on external financing.
VEPPANU Expands Oncology OpportunityThe VEPPANU license adds a differentiated oncology product to Rigel’s commercial platform and broadens its addressable market beyond hematology. Exclusive global rights could create a meaningful long-term growth engine if launch execution converts the product’s regulatory and clinical profile into adoption.
Bears Say
Declining Trailing RevenueThe latest trailing revenue contraction signals that overall commercial momentum is not yet consistently accelerating across the portfolio. A sustained decline could limit operating leverage, reduce resources available for pipeline investment, and make the company more dependent on successful new-product launches.
Reduced Liquidity After VEPPANU TransactionThe sharp reduction in cash reserves lowers near-term financial flexibility just as Rigel is funding commercial expansion and clinical programs. Less liquidity leaves a smaller buffer for development delays, launch costs, or weaker product performance and may constrain future capital allocation.
VEPPANU Obligations May Pressure EconomicsVEPPANU’s substantial upfront, milestone, royalty, and development commitments could absorb a meaningful portion of future product economics. These obligations may pressure margins and cash generation, making the commercial success and scale of the launch important to overall returns.
Rigel News
RIGL FAQ
What was Rigel’s price range in the past 12 months?
Currently, no data Available
What is Rigel’s market cap?
Rigel’s market cap is CHF715.70M.
When is Rigel’s upcoming earnings report date?
Rigel’s upcoming earnings report date is Nov 10, 2026 which is in 60 days.
How were Rigel’s earnings last quarter?
Rigel released its earnings results on Aug 04, 2026. The company reported CHF0.714 earnings per share for the quarter, beating the consensus estimate of CHF0.071 by CHF0.643.
Is Rigel overvalued?
According to Wall Street analysts Rigel’s price is currently Undervalued.
Does Rigel pay dividends?
Rigel does not currently pay dividends.
What is Rigel’s EPS estimate?
Rigel’s EPS estimate is 0.75.
How many shares outstanding does Rigel have?
Currently, no data Available
What happened to Rigel’s price movement after its last earnings report?
Rigel reported an EPS of CHF0.714 in its last earnings report, beating expectations of CHF0.071. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Rigel?
Currently, no hedge funds are holding shares in CH:RIGL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rigel Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
CHF52.57 (― Upside)
CHF52.57 (― Upside)
Blogger Sentiment
Bullish
CH:RIGL Sentiment 83%
Sector Average 61%
Sector Average 61%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
31.42%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
152.04%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Rigel
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor, which is being advanced to Phase 1b study for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center (MDACC) for the development of olutasidenib in AML and other hematologic cancers with IDH1mutations; and the Collaborative Network for Neuro-Oncology Clinical Trial (CONNECT) to conduct a Phase 2 clinical trial to evaluate olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
RIGL Company Deck
RIGL Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple meaningful commercial and pipeline achievements—most notably the in‑license and imminent launch of VEPPANU with strong phase III efficacy, ongoing commercial revenue growth (14% product sales growth, record TAVALISSE quarter, 27% REZLIDHIA growth), and promising early R289 data with regulatory incentives. These positives are tempered by lower year‑over‑year net income (partly due to one‑time prior‑year items), a substantial decline in cash reserves (~38.5%), higher operating expenses (+~35.7%), modest decline in GAVRETO sales, and significant upfront/milestone/royalty obligations tied to VEPPANU that may pressure margins and cash flow. Overall, the company communicated confident launch readiness and an optimistic strategic trajectory but with near‑term financial and execution risks to monitor.View all CH:RIGL earnings summaries